Katerzia FDA Approval History
FDA Approved: Yes (First approved July 8, 2019)
Brand name: Katerzia
Generic name: amlodipine benzoate
Dosage form: Oral Suspension
Company: Azurity Pharmaceuticals
Treatment for: High Blood Pressure, Coronary Artery Disease
Katerzia (amlodipine benzoate) is a calcium channel blocker in an oral suspension formulation indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, and coronary artery disease in adults.
Development Timeline for Katerzia
|Jul 10, 2019||FDA Approves Katerzia (amlodipine) Oral Suspension for Pediatric Patients 6 Years of Age and Older|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.